Gemcitabine and Carboplatin for Elderly Patient With Lung Cancer
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
A comparison of biweekly combination chemotherapy (gemcitabine plus carboplatin) with weekly
gemcitabine in elder patients (> 75) with previously untreated advanced non-small cell lung
cancer. Primary objective is to determine the objective response rate (CR+PR by RECIST
criteria) for biweekly gemcitabine and carboplatin combination chemotherapy versus weekly
single gemcitabine as first-line therapy in elder advanced non-small lung cancer patients (>
76 years) who have received no prior treatment for non-small lung cancer. As secondary
objectives, adverse event profile, tolerability of biweekly gemcitabine and carboplatin
combination chemotherapy, progression-free survival and overall survival will be evaluated in
both patients with biweekly gemcitabine and carboplatin combination chemotherapy and weekly
single gemcitabine.
The study hypothesis is that biweekly combination chemotherapy of gemcitabine plus
carboplatin may improve the efficacy.